OSCR vs PACS

Oscar Health exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational inefficiency. While the company maintains a low Price-to-Sales ratio (0.48) and steady revenue growth of 17.3%, it continues to struggle with negative profit margins and a consistent failure to meet earnings estimates (0/4 beats in the last year). The recent 60.9% one-month price surge appears disconnected from fundamentals, as the stock now trades above the analyst target price of $16.10. Combined with aggressive insider selling by the CFO and CTO, the risk-reward profile is unfavorable.

PACS presents a high-growth profile tempered by significant financial leverage and mediocre fundamental health, as evidenced by a Piotroski F-Score of 4/9. While the stock trades near its growth-based intrinsic value ($35.99) and shows an attractive PEG ratio of 1.02, it is priced at a massive premium to its Graham Number ($12.88). Explosive earnings growth is offset by a poor track record of meeting analyst estimates and a high Debt/Equity ratio of 3.78. The divergence between 'Strong Buy' analyst ratings and bearish insider/technical signals suggests a period of volatility ahead.